Aditxt (ADTX) shared a milestone for its target acquisition, Appili Therapeutics (APLIF), announcing that the FDA has provided “positive” feedback regarding the development strategy for ATI-1801.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADTX:
- Appili Therapeutics announces FDA alignment on ATI-1801 NDA requirements
- Aditxt Enters Major Investment Agreement with Evofem
- Aditxt CEO Clarifies NASDAQ Compliance and Capital Strategy
- Appili Therapeutics mails circular in connection with special meeting
- Aditxt provides update on plans for 2024 year-end, accessing strategic capital